European CHMP adopts positive opinion for Eviplera(R)
23 September 2011 | By Gilead Sciences, Inc.
CHMP, has adopted a positive opinion on the company's Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)...
List view / Grid view
News
Positive opinion on the usage of Levemir® (insulin detemir) as add-on therapy to Victoza® (liraglutide) in people with type 2 diabetes
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir®...
Positive opinion on the use of Levemir® (insulin detemir) in children with type 1 diabetes aged two to five years
23 September 2011 | By Novo Nordisk
CHMP has adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir...
New study shows investigational BIBF 1120 demonstrated positive trend in reducing lung function loss in Idiopathic Pulmonary Fibrosis
22 September 2011 | By Boehringer Ingelheim
Phase II clinical trial results...
Sygnature Chemical Services becomes Sygnature Discovery
21 September 2011 | By Sygnature Discovery Limited
Sygnature Chemical Services, has become Sygnature Discovery to better reflect its Integrated Drug Discovery Service-Offering...
Viramune® (nevirapine) prolonged-release once-daily formulation receives approval in the EU
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
Sanofi Pasteur acquires exclusive, worldwide license for acne vaccine and treatment
21 September 2011 | By Sanofi Pasteur
The pre-clinical vaccine was developed by researchers at the University of California...
Lilly steps up efforts to improve diversity in clinical trials
20 September 2011 | By Eli Lilly and Company
Observational study leads to systemic approach to improve minority enrollment...
Bristol-Myers Squibb and Ono enter into strategic agreement
20 September 2011 | By Bristol-Myers Squibb
Strategic agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)...
Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers
19 September 2011 | By Roche
Data show greater understanding of disease pathways and personalising treatments...
Merck’s ISENTRESS® (raltegravir) in combination therapy demonstrated efficacy and tolerability in an observational trial
19 September 2011 | By
Results from the REALMRK clinical study...
Tecan’s Cavro® Omni Robot opens up new applications for modern circular dichroism
15 September 2011 | By kdm communications limited
Cavro® Omni Robot incorporated into Applied Photophysics’ new protein discovery solution...
GSK and McLaren Group announce innovative strategic partnership
15 September 2011 | By GSK
GlaxoSmithKline announced that it has formed a long term strategic partnership with McLaren Group...
Pfizer extends subsequent offering period of tender offer to acquire Icagen, Inc.
13 September 2011 | By Pfizer
Eclipse, extended the expiration date of the subsequent offering period of its tender offer...
Novartis increases growth potential through integration of Alcon
13 September 2011 | By Novartis
Alcon to accelerate growth through Novartis strength in market access, reimbursement, and research capability...
